Heart & blood pressure · Port Charlotte, FL
Heart and blood pressure studies in Port Charlotte, FL
8 recruiting studies have a site in Port Charlotte.
8 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Boehringer Ingelheim
- Location
- Port Charlotte, FL + 91 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Boehringer Ingelheim
- Location
- Port Charlotte, FL + 78 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim
- Location
- Port Charlotte, FL + 199 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Port Charlotte, FL + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
AstraZeneca
- Location
- Port Charlotte, FL + 104 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
AstraZeneca
- Location
- Port Charlotte, FL + 206 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences GmbH
- Location
- Port Charlotte, FL + 47 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
DalCor Pharmaceuticals
- Location
- Port Charlotte, FL + 112 other US sites
- Eligibility basics
- Ages 45+
Who these studies look for
Many require a diagnosis or specific lab values such as LDL cholesterol or blood pressure readings, and exclude recent heart events.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.